Resilient Biotics is utilizing big data analytics to design microbiome-based therapeutics and advanced screening methods for prevention and precision treatment of deadly infectious diseases. Our goal is to provide more effective treatment strategies while reducing dependency on antibiotics.
Who We Are
We are a team of passionate scientists with expertise in microbial systems, developing new microbiome products, and making sense of big data. We believe longstanding challenges in diseased ecosystems can be addressed by creating resilient microbiome communities.
Chief Executive Officer and Co-founder
Chris has an extensive background in microbial systems and brings more than 15 years of microbiome research and product development experience. He has been a scientific leader at several microbiome-focused companies, and his experience encompasses all parts of the microbiome product life cycle including discovery bioinformatics, strain isolation and characterization, scale-up, and product formulation.
Chief Technical Officer and Co-founder
Greg has over 20 years of experience developing large scale intelligent analytics for organizations including Pfizer, Sugen, The Joint Genome Institute, Cemax, The Max Planck Institute, 23andMe, Amyris, and Zymergen. His work has featured the application of artificial intelligence and machine learning to produce high-impact solutions to real-world problems.
Nicole's expertise in microbiology and molecular biology spans ten years of biomedical research. Her interest has focused on microbial behavior, with research in respiratory microbiomes, bacterial genetics, and nutrient interactions in microbial communities.
Resilient Biotics utilizes deep sequencing and a machine learning-based computational platform to characterize host genotypes, commensal microbial communities, and pathogen strain variants for unprecedented microbiome resolution. Our analytics rapidly identify important genetic elements and key microbial strains that influence states of health and disease.
We sift through terabases of data to uncover unique signatures associated with disease occurrence. Our comprehensive profiling methods characterize infectious microorganisms across the entire genome in order to identify important pathogenic strains and virulence-causing genes. Our in-house heuristic search methods can rapidly pinpoint diagnostic biomarkers for pathogen identification and risk prediction. Importantly, accurate disease profiling enables the use of targeted therapeutic and disease management strategies.
Healthy microbiome communities promote host health and resist invasion by infectious pathogens. However, a robust and diverse microbial community can have thousands to hundreds of thousands of microbial strains. Our task is to parse through each of these strains to identify those responsible for positive health outcomes and pathogen resistance. Using pattern recognition and network algorithms, we identify specific microbial strains that are beneficial to the host and prevent pathogen colonization.
Resilient Biotics is actively developing live biotherapeutics to address major infectious diseases of the respiratory tract in production animal systems.